null

Ipilimumab (Anti-CTLA-4) Biosimilar In Vivo Antibody

SKU:
IVMB0217
Product Type:
Biosimilar In Vivo Antibody
Protein:
CTLA-4
Clone:
MDX-010
Isotype:
IgG1 kappa
Reactivity:
Human
Synonyms:
CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3
$299 - $8,135
Frequently bought together:

Description

system_update_altDatasheet
Product Name:Ipilimumab (Anti-CTLA-4) Biosimilar In Vivo Antibody
Product Code:IVMB0217
Clone:MDX-010
Protein:CTLA-4
Product Type:Biosimilar Recombinant Human Monoclonal Antibody
Synonyms:CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3
Isotype:Human IgG1κ
Reactivity:Human
Immunogen:Human CTLA-4
Applications:B, CyTOF®, ELISA, FC
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Applications:B, CyTOF®, ELISA, FC
Recommended Usage:FC
The suggested concentration for Ipilimumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 µg per 106 in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
Reactivity:Human
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only.
Antigen Distribution:CTLA4 is constitutively expressed in regulatory T cells.
Immunogen:Human CTLA-4
Concentration:≥ 5.0 mg/ml
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Cytotoxic T-lymphocyte�associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body�s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body�s own immune response against cancer cells.�2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.
Protein:CTLA-4
Research Area:Immunology

Related Products